| Jul 11 |
Bausch Health to Announce Second Quarter 2024 Results on August 1, 2024
|
| Jul 8 |
RBC Capital on Bausch + Lomb's Miebo, Xiidra, Prescription Numbers
|
| Jun 20 |
Bausch Health Brings Patent Infringement Lawsuit Against Norwich Pharmaceuticals
|
| Jun 16 |
With 63% ownership of the shares, Bausch Health Companies Inc. (NYSE:BHC) is heavily dominated by institutional owners
|
| Jun 14 |
Bausch Health Reports Promising R&D Trial Updates on Amiselimod and Scientific Data Presented at International Healthcare Conferences
|
| May 29 |
Bausch + Lomb’s enVista Envy IOL obtains Health Canada approval
|
| May 23 |
Bausch Health, Canada Inc. Announces Additional Public Drug Plan Listings for PrUCERIS(R) (Budesonide) Aerosol Foam To Treat Mild to Moderate Distal Ulcerative Colitis in Adults
|
